HEMATOLOGICAL MALIGNANCIES: LEUKEMIAS, LYMPHOMAS AND MYELOMAS

VolverGo back

Resultados 24 results. LastUpdate Updated on 05/12/2021 [08:40:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



1   results/page


COMPOSITIONS FOR DETECTING MUTANT ANAPLASTIC LYMPHOMA KINASE IN LUNG CANCER

Publication No.: US2021371933A1 02/12/2021

Applicant:

CELL SIGNALING TECHNOLOGY INC [US]

US_2019127804_A1

Absstract of: US2021371933A1

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have been identified herein in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides.

traducir

CONJUGATED ANTIBOIDES AGAINST LY75 FOR THE TREATMENT OF CANCER

Publication No.: US2021371541A1 02/12/2021

Applicant:

OXFORD BIOTHERAPEUTICS LTD [GB]

ES_2859604_T3

Absstract of: US2021371541A1

The invention provides antibodies which bind to LY75. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer, esophageal cancer, skin cancer, thyroid cancer, lung cancer, bladder cancer, multiple myeloma and lymphoma.

traducir

BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20

Publication No.: US2021371538A1 02/12/2021

Applicant:

GENMAB AS [DK]

WO_2021224499_A1

Absstract of: US2021371538A1

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

traducir

IDENTIFICATION OF PDE3 MODULATOR RESPONSIVE CANCERS

Publication No.: US2021371935A1 02/12/2021

Applicant:

BROAD INST INC [US]

CA_3122378_A1

Absstract of: US2021371935A1

The present disclosure features methods for identifying pateints having a hyperproliferative disease, disorder, or condition responsive to phosphodiesterase 3 (PDE3) and schlafen family member 12 (SLFN12) complex formation. The hyperproliferative disease, disorder, or condition may be cancer in a patient including glioblastoma, melanoma, ovarian cancer, cervical cancer, sarcoma, or hematopoietic cancers, such as acute myeloid leukemia. Those responsive diseases, disorders, or conditions may be identified using the biomarker AIP and/or TRRAP in combination with those biomarkers pertinent to phosphodieseterase 3 and schlafen family member 12 complexes which may be formed by PDE3 modulation with certain active compounds. Expression of combinations of these biomarkers have been shown to correlate with active compound (e.g., PDE3 modulator, PDE3A modulator, PDE3B modulator) sensitivity.

traducir

COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA

Publication No.: US2021363248A1 25/11/2021

Applicant:

INNATE PHARMA [FR]

EP_3896088_A1

Absstract of: US2021363248A1

The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

traducir

Methods of administering chimeric antigen receptor immunotherapy

Publication No.: AU2020267378A1 25/11/2021

Applicant:

KITE PHARMA INC [US]

Absstract of: AU2020267378A1

The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.

traducir

Chromosome conformation markers of prostate cancer and lymphoma

Publication No.: AU2020268861A1 25/11/2021

Applicant:

OXFORD BIODYNAMICS PLC [GB]

TW_202108773_PA

Absstract of: AU2020268861A1

A process for analysing chromosome regions and interactions relating to prognosis of prostate cancer or DLBCL.

traducir

Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma

Publication No.: AU2020275415A1 25/11/2021

Applicant:

GENENTECH INC [US]

TW_202108178_A

Absstract of: AU2020275415A1

Provided herein are methods of treating B-cell proliferative disorders (such as Follicular Lymphoma "FL") using immunoconjugates comprising anti-CD79b antibodies in combination with an immunomodulatory agent (such as lenalidomide) and an anti-CD20 antibody (such as obinutuzumab or rituximab).

traducir

4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER

Publication No.: US2021363170A1 25/11/2021

Applicant:

SOUTHERN RES INST [US]

JP_2021522197_A

Absstract of: US2021363170A1

The present disclosure is concerned with 4′-thio nucleotide and nucleoside compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

traducir

NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Publication No.: US2021363121A1 25/11/2021

Applicant:

UNIV DEGLI STUDI ROMA LA SAPIENZA [IT]
FONDAZIONE ST ITALIANO TECNOLOGIA [IT]

WO_2018122689_PA

Absstract of: US2021363121A1

Compounds of formula (I) in the capacity of compounds with anti-tumor activity for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).

traducir

PYRIDINE ACETAMIDE DERIVATIVE SERVING AS CDK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Publication No.: WO2021227906A1 18/11/2021

Applicant:

SUZHOU ALPHAMA BIOTECHNOLOGY CO LTD [CN]

CN_113173924_A

Absstract of: WO2021227906A1

The present invention relates to the technical field of pyridine acetamide derivatives, and specifically relates to a pyridine acetamide derivative serving as a CDK inhibitor, and a preparation method therefor and a use thereof. The pyridine acetamide derivative exhibits excellent CDK9/CDK7 enzyme inhibitory activity, and can be used for preparing a medication for treating cancers; and the cancers particularly are blood cancers, including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like, and solid tumors, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

traducir

INTERLEUKIN-8 FOR MAINTENANCE OF HUMAN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME AND USES THEREOF

Publication No.: US2021355501A1 18/11/2021

Applicant:

ALBERT EINSTEIN COLLEGE OF MEDICINE [US]

WO_2020068615_PA

Absstract of: US2021355501A1

Methods are disclosed for enhancing growth of a human acute myeloid leukemia (AML) sample, a human myelodysplastic syndrome (MDS) sample, a human IL-8 dependent tumor sample, human preleukemia cells, and a human preleukemia clone or subclone ex vivo or in a xenograft animal model comprising adding human interleukin-8 (hIL-8) or a hIL-8 agonist to the sample or administering hIL-8 or a hIL-8 agonist to the animal model or expressing a gene encoding hIL-8 or a hIL-8 agonist in the animal model. The invention also provides a transgenic animal that expresses a gene encoding human interleukin-8 (hIL-8) or a hIL-8 agonist, which can be used to test the effectiveness of treatments for AML, MDS and IL-8 dependent tumors.

traducir

POLYCYCLIC AMIDE DERIVATIVE AS CDK9 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF

Publication No.: WO2021227904A1 18/11/2021

Applicant:

SUZHOU ALPHAMA BIOTECHNOLOGY CO LTD [CN]

CN_113149996_A

Absstract of: WO2021227904A1

A polycyclic amide derivative as a CDK9 inhibitor, and a preparation method therefor and use thereof. The polycyclic amide derivative exhibits an excellent CDK9 enzyme inhibitory activity, and can be used for preparing a medicine for treating cancers, wherein the cancers are especially hematological cancers, including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and solid tumors including breast cancer, prostate cancer, ovarian cancer, hepatocellular cancer, pancreatic cancer, renal cancer, gastric cancer, colorectal cancer and lung cancer.

traducir

COMPOSITIONS AND METHODS FOR TREATING CANCER

Publication No.: WO2021227326A1 18/11/2021

Applicant:

ADAGENE AG [CH]
LUO PETER PEIZHI [CN]

WO_2021226883_A1

Absstract of: WO2021227326A1

Provided herein are compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. In some embodiment, combination therapies including the anti-CD137 antibody and an immune checkpoint inhibitor, and/or a chemotherapeutic agent are provided. Biomarkers such as total CD137, membrane bound CD137 (mCD137), soluble CD137 (sCD137), CD137 ligand, Ki67, CD8+ effector memory T (Tem) cells, regulatory T (Treg) cells, and natural killer (NK) cell levels for the methods of treatment described herein are also provided.

traducir

COMPOSITIONS AND METHODS FOR TREATING CANCER SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

Publication No.: WO2021226883A1 18/11/2021

Applicant:

ADAGENE AG [CH]
LUO PETER PEIZHI [CN]

WO_2021227326_A1

Absstract of: WO2021226883A1

Provided are compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. Biomarkers such as membrane bound CD137 (mCD137), soluble CD137 (sCD137) and Ki67 for the methods of treatment are also provided.

traducir

COMPOSITIONS AND METHODS FOR TREATING CANCER

Publication No.: WO2021227156A1 18/11/2021

Applicant:

ADAGENE AG [CH]
LUO PETER PEIZHI [CN]

WO_2021227326_A1

Absstract of: WO2021227156A1

Provided are compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. Combination therapies including the anti-CD137 antibody and an immune checkpoint inhibitor, and/or a chemotherapeutic agent are provided. Biomarkers such as membrane bound CD137 (mCD137), soluble CD137 (sCD137) and Ki67 for the methods of treatment are also provided.

traducir

COMPOSITIONS AND METHODS FOR TREATING CANCER

Publication No.: WO2021228178A1 18/11/2021

Applicant:

ADAGENE AG [CH]
LUO PETER PEIZHI [CN]

Absstract of: WO2021228178A1

The present application provides compositions and methods for treating cancers, including follicular lymphoma, T cell lymphoma and adenoid cystic carcinoma, using an anti-CD137 antibody that specifically binds to an extracellular domain of human CD137. In some embodiment, combination therapies including the anti-CD137 antibody and an immune checkpoint inhibitor, and/or a chemotherapeutic agent are provided. Biomarkers such as total CD137, membrane bound CD137 (mCD137), soluble CD137 (sCD137), CD137 ligand, Ki67, CD8+ effector memory T (Tem) cells, regulatory T (Treg) cells, and natural killer (NK) cell levels for the methods of treatment described herein are also provided.

traducir

USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER

Publication No.: WO2021231639A1 18/11/2021

Applicant:

IGM BIOSCIENCES INC [US]

Absstract of: WO2021231639A1

This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a cancer therapy, e.g., radiation, an anthracycline, a folic acid analog, a platinum-based agent, a taxane, a topoisomerase II inhibitor, a SMAC mimetic, a vinca alkaloid, a Bruton's tyrosine kinase (BTK) inhibitor, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, a myeloid cell leukemia-1 (Mcl-1) inhibitor, or any combination thereof.

traducir

Dosing regimens of bispecific CD123 x CDS diabodies in the treatment of hematologic malignancies

Publication No.: AU2020272734A1 18/11/2021

Applicant:

MACROGENICS INC [US]

CN_113728009_A

Absstract of: AU2020272734A1

The present invention is directed to a dosing regimen for administering a CD 123 x CDS bispecific diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The present invention is also directed to a dosing regimen for administering a CD 123 x CDS bispecific diabody in combination with a molecule capable of binding PD-1 or a natural ligand of PD-1 (a "PD-1 or PD-1 ligand binding molecule") to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such regimens for administering the sequence-optimized CD 123 x CDS bispecific diabody, "DART-A," which is capable of simultaneous binding to CD 123 and CDS.

traducir

Methods, systems, and aparatus for nucleic acid detection

Publication No.: AU2020253585A1 18/11/2021

Applicant:

MISSION BIO INC [US]

US_2021277458_A1

Absstract of: AU2020253585A1

Provided herein are methods for detection and characterization of a target nucleic acid from a single cell. One embodiment is a method for detection of a BCR-ABL gene fusion in a nucleic acid sample from a single cell having or suspected of having a BCR-ABL fusion transcript. One preferred implementation of the invention includes providing a nucleic acid amplification primer set complementary to a target nucleic acid suspected of having a BCR-ABL fusion transcript. In some embodiments, one or both primers of the nucleic acid amplification primer set have a barcode identification sequence. Also provided are methods for the detection of an AML tumor, methods are used for the detection of a leukemia, for the detection of a myeloid leukemia, and to determine the prognosis of a patient suspected of having a BCR-ABL fusion transcript.

traducir

TREATMENT FOR VENETOCLAX-RESISTANT AND VENETOCLAX-SENSITIVE ACUTE MYELOID LEUKEMIA

Publication No.: US2021353619A1 18/11/2021

Applicant:

UNIV OREGON HEALTH & SCIENCE [US]

WO_2020092615_PA

Absstract of: US2021353619A1

Provided herein are methods and therapeutic combinations useful in the treatment of venetoclax-resistant Acute Myeloid Leukemia and of venetoclax-sensitive Acute Myeloid Leukemia.

traducir

MEDICINE FOR TREATING RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Publication No.: WO2021230179A1 18/11/2021

Applicant:

DAIICHI SANKYO CO LTD [JP]

Absstract of: WO2021230179A1

The purpose of the present invention is to provide a method for treating relapsed or refractory multiple myeloma. Provided are: a medicine for treating multiple myeloma, said medicine comprising a compound having an activity of inhibiting NSD2; a method for treating multiple myeloma, said method comprising administering an NSD2 inhibitor; and an NSD2 inhibitor for treating multiple myeloma.

traducir

VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS

Publication No.: US2021353741A1 18/11/2021

Applicant:

VARIATION BIOTECHNOLOGIES INC [CA]

WO_2021198769_A1

Absstract of: US2021353741A1

The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.

traducir

Composition for preventing improving and treating leukemia comprising compound derived from Rumex japonicus houtt roots extract

Nº publicación: KR20210136202A 17/11/2021

Applicant:

전남대학교산학협력단한국표준과학연구원

Absstract of: KR20210136202A

본 발명은 양제근 추출물에서 유래한 화합물을 유효 성분으로 포함하는 혈액암 예방, 개선 및 치료용 조성물에 관한 것으로, 천연물인 양제근에서 유래하여 인체 안전하면서도, 강력한 미토콘드리아 탈분극 효과를 갖고 활성산소종의 수준 증가를 보였으며, 세포 주기 진행을 지연시키고 사멸 세포의 수를 증가시켜, 백혈병 세포에서 세포사멸을 유도하는 활성을 나타내므로 혈액암의 예방 또는 치료 목적으로 활용될 수 있다.

traducir

1 results/page

punteroimgGo back